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MicroRNA-1 modulates chondrocyte phenotype by regulating FZD7 of 
Wnt/β-catenin signalling pathway 
 
ABSTRACT 
Objective: Osteoarthritis (OA) is an incurable joint disease characterised by pronounced pain. 
MicroRNAs constitute epigenetic mechanisms that may affect OA progression by contributing 
to changes in chondrocyte phenotype. This study investigates for the first time whether there 
is a link between miRNA-1 (miR-1) and OA pathogenesis, and the molecular mechanisms 
involved. 
Design: OA-associated gene expression, including MMP-13, ADAMTS5 and COL2A1 was 
compared in chondrocytes from non-OA and OA cartilage, and in SW1353 cells over- and 
under-expressing miR-1. Bioinformatics and luciferase reporter assay were conducted to 
confirm whether FZD7 was a target of miR-1. The effects of miR-1 on FZD7 expression and 
downstream Wnt/β-catenin signalling were investigated. 
Results: Non-OA and OA chondrocytes differed significantly in the expression of miR-1 and 
OA-associated genes. MiR-1 over- and under-expression in SW1353 cells respectively reduced 
and enhanced gene expression associated with cartilage catabolism. FZD7, which has an 
important role in the Wnt/β-catenin signalling pathway, was shown to be a potential target of 
miR-1. MiR-1 binding to FZD7 increased the levels of phosphorylated (inactivated) β-catenin, 
thereby preventing downstream β-catenin signalling. 
Conclusions: Inhibition of Wnt/β-catenin signalling by miR-1 in chondrocytes may attenuate 
the expression of genes that regulate the activity of catabolic enzymes. This finding may be 
useful for future investigations of molecular targets for OA treatment. 
 





Osteoarthritis (OA) is a chronic degenerative joint disease characterised by progressive 
destruction of articular cartilage that is often associated with significant pain [1]. Due to the 
irreversible nature of the disease and the lack of an effective cure, OA remains a leading cause 
of global disability for which chronic management creates a major burden for healthcare 
systems worldwide [2]. Although some common risk factors have been identified for OA, 
including age, gender, prior joint injury, obesity, genetic predisposition, and abnormal 
mechanical loading [3], the disease is idiopathic in the majority of OA patients. The 
pathogenesis of OA is complex and not fully understood, and the severity of disease symptoms 
(such as pain) can have almost no association with structural changes in the joint (such as 
cartilage and bone changes) or the phenotype of cells (such as chondrocytes). These factors 
make OA a difficult disease to treat, and the effects of current clinical therapies are typically 
limited to relieving symptoms rather than interfering with disease progression. 
 
Degenerative changes in OA are correlated with alterations in chondrocyte gene expression 
involved in maintaining the integrity and function of articular cartilage [4, 5]. Over the last 
decade, growing evidence has pointed to the important role of epigenetic mechanisms in 
modulating cell phenotype in OA [6-8]. Interactions with the environment can produce 
epigenetic alterations in gene expression that contribute to disease aetiology and are transmitted 
in a sustained manner to daughter cells throughout many doublings. Of these epigenetic 
mechanisms, microRNAs (miRNAs) are of particular interest due to their roles in maintaining 
a normal chondrocyte phenotype and controlling inflammatory response pathways [7], which 
may affect OA disease progression. miRNAs are a class of small, non-coding single-stranded 
RNAs of 20-25 nucleotides that regulate gene expression at the post-transcriptional level, 
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affecting cell fate during proliferation and differentiation [9]. This regulatory mechanism 
involves sequence-specific interactions with the 3’-untranslated regions (3’-UTRs) of specific 
mRNA targets, leading to mRNA degradation and/or translational repression [10]. 
 
Almost one third of mammalian mRNA expression is regulated by miRNAs [11], which have 
diverse but critical functions in tissue development and disease [12, 13].  Alterations in the 
expression of miRNAs are found to be closely related to chondrogenesis and OA [14, 15]. A 
range of miRNAs have been explored in this regard and some of their specific roles in 
regulating chondrocyte activity and OA pathogenesis have been elucidated [16, 17]. For 
instance, miR-140 is a cartilage-specific miRNA that is expressed during embryogenesis and 
adult articular cartilage, with important roles in OA pathogenesis through the regulation of 
ADAMTS-5 and IGFBP-5 [18, 19]. Other relatively well-investigated miRNAs which are 
differentially expressed in OA and/or have important roles in OA pathogenesis include miR-
27 [19, 20], miR-34a [21], miR-146 [14, 22] and miR-675 [23].  
 
Proteins of the Wnt/β-catenin pathway are known to be over-expressed in the joints of OA 
patients and in animal models of disease, and pathway activation is thought to contribute to 
chondrocyte and matrix degradation in joint pathologies [24, 25]. Despite there being a range 
of studies investigating the roles of various miRNAs in OA, there is insufficient evidence to 
suggest that these affect Wnt/β-catenin signalling as one of the major pathways modulating OA 
progression. In this context, we have identified miR-1 as a possible epigenetic link between 
Wnt/β-catenin signalling and OA. MiR-1 has been shown to modulate the activity of the Wnt/β-
catenin pathway, which in one study promoted cardiomyocyte differentiation in pluripotent 
stem cells and suppressed their commitment to becoming endothelial cells [26]. The same study 
also identified FZD7 as a new miR-1 target. However, the only known association between 
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miR-1 and joint pathology is that miR-1 plays an important role in regulating the chondrocyte 
phenotype and the late stage of chondrogenic differentiation, thereby contributing to cartilage 
integrity [27]. Interestingly, there has been more evidence suggesting that changes in miR-1 
are correlated with other diseases that often occur as co-morbidities of OA [28], including 
cardiovascular disease [29] and Parkinson’s disease [30]. Based on this information, we 
hypothesised that non-OA and OA chondrocytes may have different levels of miR-1 expression, 
and that over-expression of miR-1 may inhibit OA pathogenesis by targeting FZD7 of the 
Wnt/β-catenin signalling pathway. This is the first study to define a link between miR-1 and 
OA, where miR-1 over-expression was found to inhibit the expression of catabolic genes 




2.1 Tissue samples and chondrocyte isolation 
This research was approved by the Ethics Committee of XXXX (2014-002). All methods were 
carried out in accordance with relevant guidelines and regulations. Discarded cartilage tissues 
were obtained from 10 non-OA patients undergoing traumatic above-knee amputation and 10 
OA patients undergoing total knee replacement surgery. The OA patients were clinically 
diagnosed to be Kellgren-Lawrence (K-L) grade 3–4 based on radiographic examination. All 
clinical specimens were obtained after patients gave informed written consent. The two groups 
were paired and cartilage samples were matched by age, sex and body mass index 
(Supplementary Table 1). 
 
Chondrocytes were isolated from the articular cartilage of clinical specimens obtained from 
non-OA and OA patients. Cartilage samples were enzymatically digested using 0.15% (w/v) 
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collagenase (CLS-2, Worthington, USA) for 16 h at 37°C in maintenance medium. Isolated 
chondrocytes were washed in PBS and filtered using 100 μm cell strainers (BD Biosciences, 
USA). The cells were seeded at high density (1 × 104 cells/cm2) and kept in maintenance 
medium for 2 days prior to gene expression analysis. Maintenance medium consisted of 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, UK) supplemented with 10% foetal 
bovine serum (FBS, HyClone, USA), 100 U/mL penicillin (Gibco) and 100 mg/mL 
streptomycin (Gibco). 
 
2.2 SW1353 cell culture and transfection 
Human chondrosarcoma cells (SW1353) were obtained from the American Type Culture 
Collection (ATTC). Cells were grown in DMEM supplemented with 10% FBS at 37°C with 
5% CO2. The cells were transfected with miR-1 agomir (miR-1 agonist; 5’-
UGGAAUGUAAAGAAGUAUGGAG-3’), miR-1 antagomir (miR-1 antagonist; 5’-
CUCCAUACUUCUUUACAUUCCA-3’), and agomir and antagomir negative controls (NC; 
5’-UUCUCCGAACGUGUCACGUTT-3’ and 5’-UUGUACUACACAAAAGUACUG-3’) 
which were scrambled miRs (RiboBio, China), using Lipofectamin 2000 (Invitrogen, USA) 
according to the manufacturer’s instructions. Transfected cells were kept in maintenance 
medium and gene expression analysis was conducted 48 h post-transfection. 
 
2.3 Plasmid construction 
For the FZD7 3’UTR reporter assay, the psiCHE-FZD7 3’UTR-wt plasmid was constructed by 
annealing the sense and antisense strands of the putative binding site sequence for miR-1, and 
inserting the annealed sequence downstream of the stop codon of the Renilla luciferase gene 
in the psiCHECK-2 dual-luciferase reporter plasmid (Promega). The psiCHE-FZD7 3’UTR-
mt plasmid was constructed using a mutated sequence (randomly disorganised seed region) in 
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the putative binding site for miR-1. To construct the FZD7 over-expression vector (3.1-FZD7), 
the FZD7 coding sequence was amplified by PCR and cloned into the Nhel and Xhol sites in 
the pcDNA3.1 vector (Invitrogen). 
 
2.4 Bioinformatics and luciferase reporter assay 
FZD7 was predicted to be a prime target of miR-1 using the TargetScanHuman search program 
(www.targetscan.org). The complementary sequences in miR-1 and FZD7 mRNA were 
confirmed by microRNA.org.  
 
SW1353 cells were grown at a density of 5.5 × 104 cells/cm2 in 48-well plates. The cells were 
transfected with psiCHECK-2 recombination vector (50 ng), together with miR-1 agomir 
(miR-1) or agomir negative control (NC). At 48 h after transfection, Firefly luciferase and 
Renilla luciferase activities were measured using the Dual-Glo Luciferase Assay System 
(Promega) with a Synergy 2 Multi-Mode microplate reader (Biotek, USA). 
 
2.5 Gene expression analysis 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions. Briefly, after homogenising samples using the TRIzol reagent, 
chloroform was added and RNA was precipitated using isopropanol. The RNA was 
resuspended in 20 μL purified water.  
 
For each sample, reverse transcription into cDNA was performed using 1 μg total RNA using 
M-MLV reverse transcriptase (Promega, USA) according to the manufacturer’s instructions. 
Gene expression levels were quantified using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems, USA) and normalised to GAPDH. Primer sequences were purchased from Sigma-
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Aldrich. For miR-1, reverse transcription and PCR reactions were performed using the All-in-
One miRNA qRT-PCR Detection Kit (GeneCopoeia, USA) with primers for mature miRNA 
hsa-miR-1-3p (No. HmiRQP0044). MiR-1 expression levels were normalised to U6. Relative 
expression for all genes were calculated using the comparative Ct (2−ΔΔCT) method. 
 
2.6 Western blotting 
Cells were lysed using a cell lysis buffer (Beyotime, China) with a protease inhibitor cocktail 
(Sigma) and phosphatase inhibitors (5 mM Na4P2O7, 50 mM NaF, 1 mM vanadate). The protein 
content of the lysate was quantified using a BCA assay. Total protein (20 μg) from each sample 
was electrophoresed on 12% (w/v) SDS-PAGE and transferred to a 0.45 μm PVDF membrane 
(Sigma), which were blocked for 2 h with 5% skim milk. The membranes were incubated at 
4°C overnight with rabbit monoclonal antibodies (CST, China) anti-FZD7 (No. 3975), anti-
Cyclin (No. 4138), anti-c-Myc (No. 9402), and anti-GAPDH (No. 5174). Monoclonal anti-β-
catenin (No. 8480) and monoclonal anti-phospho β-catenin (No. 4176) antibodies were 
respectively used to detect total β-catenin and non-active (phosphorylated) β-catenin. 
Secondary antibodies conjugated to horseradish peroxidase (HRP) were added for 1 h. The 
blots were visualised using enhanced chemiluminescence (ECL) reagent (Thermo Fisher 
Scientific, USA). The blot intensity was quantified using molecular imaging software 
(Carestream Health, USA) after normalising to the corresponding loading control. 
 
2.7 Statistical analysis 
Data for all experiments were obtained from at least three independent samples, and all results 
were expressed as mean ± standard deviation (SD). Statistical analysis was performed using 
SPSS 13.0 (SPSS, USA). One-way ANOVA with Tukey’s multiple comparisons test was used 





3.1 Gene expression profile of chondrocytes from non-OA and OA patients 
Chondrocytes isolated from knee cartilage of non-OA and OA patients were tested for 
differences in OA-related gene expression. Compared to non-OA chondrocytes, the expression 
level of COL2A1 was decreased in OA chondrocytes, while the expression levels of MMP-9, 
MMP-13, BMP-2 and ADAMTS5 were increased (Figure 1A). OA chondrocytes also showed 
significantly lower miR-1 expression level than non-OA chondrocytes (Figure 1B, P<0.0001).  
 
Figure 1. Gene expression profile of chondrocytes from non-OA and OA patients. 
Expression levels of (A) OA-related genes and (B) miR-1 in chondrocytes isolated from non-
OA and OA cartilage. The OA group is expressed as a fold difference from the non-OA group. 
N = 10 (independent samples). *P<0.05, ****P<0.0001. 
 
3.2 Effect of miR-1 over-expression on the gene expression profile of SW1353 cells 
SW1353 cells transfected with miR-1 antagomir, miR-1 agomir, and negative controls (NC) 
were tested for the expression of miR-1 and OA-related genes at 48 h post-transfection. Cells 
transfected with miR-1 antagomir showed lower miR-1 expression compared to the NC group 
(P<0.05), while miR-1 expression in cells transfected with miR-1 agomir were significantly 
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higher than the NC group (P<0.0001) (Figure 2A). These results confirmed the transfection 
efficiency of the miR-1 agomir and antagomir and stability of the expressed product for use in 
the subsequent experiments. 
 
The inhibition of miR-1 expression in SW1353 cells caused significant increases in the 
expression of genes associated with cartilage catabolism, as well as greatly reduced COL2A1 
expression (Figure 2B-2F). In contrast, miR-1 over-expression displayed opposite trends, 
where the expression of MMP-9, MMP-13, BMP-2 and ADAMTS5 were inhibited while the 




Figure 2. Effect of miR-1 over-expression on the gene expression profile of SW1353 cells. 
Expression levels of (A) miR-1, (B) MMP-9, (C) MMP-13, (D) BMP-2, (E) ADAMTS5 and 
(F) COL2A1 in SW1353 cells at 48 h post-transfection with miR-1 antagomir, miR-1 agomir, 
and negative controls. Antagomir and agomir groups are expressed as a fold difference from 





3.3 miR-1 regulation of FZD7 expression 
To determine the mechanism by which miR-1 inhibits the expression of genes associated with 
cartilage catabolism, we investigated a potential target of miR-1. FZD7, as a key component 
of the Wnt/β-catenin signalling pathway, was predicted by the TargetScan database as a prime 
target of miR-1, with a highly conserved complementary miR-1 binding site in its 3’UTR 
across vertebrates from humans to cows (Figure 3A, 3B). 
 
To confirm that FZD7 is a target for miR-1, sequences of wild-type 3’UTR of FZD7 containing 
the putative binding site for miR-1 were synthesised and inserted downstream of the luciferase 
gene in SW1353 cells. Renilla luciferase expression was inhibited in SW1353 cells when the 
construct (psiCHE-FZD7 3’UTR-wt) was co-transfected with miR-1 agomir compared to the 
NC control (P<0.01) (Figure 3C). In contrast, no appreciable inhibitory effect was observed 
when the miR-1 agomir was co-transfected with the empty vector (psiCHECK-2) or the mutant 
reporter (psiCHE-FZD7 3’UTR-mt). The results of the luciferase assay indicated that the 
predicted binding site is a potential target of miR-1.  
 
To examine whether miR-1 can regulate FZD7 expression, the levels of FZD7 mRNA and 
protein expression were measured in SW1353 cells transfected with miR-1 agomir, miR-1 
antagomir, and negative controls (NC). At 48 h post-transfection, FZD7 mRNA expression was 
significantly reduced in the miR-1 agomir group but significantly increased in the miR-1 
antagomir group (Figure 3D). The same trends were observed for FZD7 protein expression 
measured through western blotting (Figure 3E) and densitometry analysis (Figure 3F). These 
results provided evidence that FZD7 was regulated by miR-1, whereby its expression was 




Figure 3. MiR-1 regulation of FZD7 expression. (A, B) The predicted binding site of miR-1 
in the 3’UTR of FZD7 is highly conserved among vertebrates. (C) Luciferase assay to confirm 
that the predicted binding site in FZD7 could be a target of miR-1. mt = mock vector. The 
expression levels of FZD7 (D) mRNA and (E, F) protein by western blotting and densitometry 
analysis in SW1353 cells at 48 h post-transfection with miR-1 antagomir, miR-1 agomir, and 
negative controls. Antagomir and agomir groups are expressed as fold difference from NC 
groups. N = 3 (independent samples), technical replicates for qRT-PCR = 3. *P<0.05, 




3.4 Effect of miR-1 on Wnt/β-catenin signalling pathway 
FZD7 is a transmembrane receptor for Wnt/β-catenin signalling. After being transfected to 
induce or inhibit miR-1 expression, the total β-catenin protein levels in SW1353 cells remained 
similar among groups, but the levels of non-active (phosphorylated) β-catenin were 
significantly elevated in the miR-1 agomir group and significantly reduced in the miR-1 
antagomir group compared to NC controls (Figure 4A). These results suggested that miR-1 
over-expression inhibited the activation of the Wnt/β-catenin pathway, preventing large 
amounts of activated β-catenin in the cytoplasm from translocating into the nucleus and 
stimulating β-catenin-dependent gene transcription. 
 
In addition, we examined the mRNA and protein expression of Cyclin D1 and c-Myc, which 
are well-known downstream targets of Wnt/β-catenin signalling. For both Cyclin D1 and c-
Myc, mRNA (Figure 4B) and protein (Figure 4C) expression were significantly reduced in 
cells transfected with miR-1 agomir but significantly increased in cells transfected with miR-1 
antagomir. Taken together, the findings suggest that FZD7 is regulated by miR-1 on the mRNA 
level, whereby interactions between miR-1 and the 3’UTR of FZD7 may reduce the stability 
of the mRNA. The reduction in FZD7 protein levels increases the levels of phosphorylated β-
catenin and reduces β-catenin activation. This leads to the downregulation of several key genes 





Figure 4. Effect of miR-1 on Wnt/β-catenin signalling pathway. The expression levels of 
(A) β-catenin and phosphorylated β-catenin proteins (left, western blotting; right, densitometry 
analysis), Cyclin D1 and c-Myc (downstream targets of β-catenin signalling) (B) mRNA and 
(C) protein (left, western blotting; right, densitometry analysis) in SW1353 cells at 48 h post-
transfection with miR-1 antagomir, miR-1 agomir, and negative controls. Antagomir and 
15 
 
agomir groups are expressed as fold difference from NC groups. N = 3 (independent samples), 
technical replicates for qRT-PCR = 3. *P<0.05, **P<0.01. 
 
4. DISCUSSION 
The pathogenesis of OA is characterised primarily by cartilage degradation accompanied by 
local inflammation. As one of the key types of epigenetic mechanisms, miRNAs are now 
understood to have essential roles in modulating and maintaining normal cartilage development 
and homeostasis [7]. Normal levels of miRNA expression are disrupted in pathological 
disorders such as OA, either as a cause or consequence of disease pathogenesis and progression 
[12]. Over 25 different miRNAs have been identified as either having altered expression in OA 
or functional implications in OA pathogenesis [16, 17]. Interestingly, miR-1 has been identified 
as having a key role in the regulation of chondrocyte hypertrophy [27], but its target in 
chondrocytes is unknown, and its effects on OA-related gene expression in chondrocytes have 
not been investigated. This is the first study to show that miR-1 is differentially expressed in 
OA compared to non-OA chondrocytes, and its under-expression in OA may lead to increased 
activation of the Wnt/β-catenin pathway that then modulates the expression of key genes 
implicated in OA pathogenesis. 
 
We found that the transcription levels of several key proteins were significantly different 
between OA and non-OA chondrocytes, including cartilage degrading enzymes (MMP-9, 
MMP-13 and ADAMTS5), markers of cartilage repair (BMP-2 [31]) and cartilage matrix 
proteins (COL2A1). These results corroborated with an increasing number of studies 
examining global gene expression profiles of OA compared to non-OA human cartilage 
samples, which reported differential expression of both anabolic and catabolic matrix genes 
[32, 33]. The OA chondrocytes in our study also showed significantly lower miR-1 expression 
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compared to non-OA chondrocytes, suggesting that its under-expression in OA may be linked 
to disease pathogenesis. 
 
To elucidate the link between miR-1 expression and OA-associated gene transcription, we 
studied the effects of miR-1 over-expression and under-expression in chondrocytes by 
transfecting SW1353 cells with a miR-1 agonist and antagonist, respectively. Although 
SW1353 is a chondrosarcoma cell line with limited similarities in gene expression profile 
compared to primary human chondrocytes, they have similar responses as primary 
chondrocytes to catabolic cytokines such as IL-1β, and have been used in many studies to 
investigate protease expression and regulation in chondrocytic cells [34], or molecular 
mechanisms of pathogenesis in OA [35-37]. In our study, we chose SW1353 cells for use as a 
reliable transfection host that replicated some of the key characteristics of chondrocytic cells. 
Using these cells, we found that miR-1 over-expression resulted in the downregulation of gene 
expression for MMP-9, MMP-13 and ADAMTS5, and essentially reversed the trends observed 
in primary OA chondrocytes with regard to the relative expression levels of OA-associated 
genes. These findings suggested an essential role of miR-1 in regulating the phenotype of 
chondrocytes and their expression of catabolic genes that may contribute to OA pathogenesis. 
 
The molecular mechanisms responsible for OA progression are highly complex and not fully 
understood. Nevertheless, several signalling pathways are known to be involved in the 
development of OA, including mitogen-activated protein kinase (MAPK), nuclear factor κB 
(NF-κB), and Wnt/β-catenin [24]. Among these, the Wnt/β-catenin pathway is particularly 
interesting as it is involved in embryonic development of cartilage and bone, and has a key 
regulatory role in joint remodelling [38]. The activation of Wnt/β-catenin signalling is thought 
to contribute to excessive cartilage matrix remodelling and degradation in joint pathologies 
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[24]. Overexpressing or preventing the degradation of β-catenin protein has been shown to 
induce an OA-like phenotype in articular chondrocytes and mouse models, and significantly 
affect the expression of chondrocyte marker genes including matrix metalloproteinases 
(MMPs), ADAMTSs, aggrecan and collagen type II [39, 40]. Studies have shown that 
molecular [41] or pharmacological [42, 43] agents inhibiting Wnt/β-catenin signalling in 
chondrocytes reduced the expression of matrix-modulating enzymes including MMPs, which 
might contribute to dampening disease progression in OA. It is well established that the Wnt/β-
catenin pathway involves the interactions of Wnt ligands with Frizzled receptors on the cell 
membrane [44]. In the absence of Wnt ligand-receptor interactions, β-catenin is phosphorylated 
and subsequently undergoes proteasomal destruction. Upon Wnt ligand-receptor interaction 
with Frizzled receptors, β-catenin is stabilised, accumulates, and can translocate to the nucleus 
to modulate the expression of specific target genes. 
 
In our study, FZD7 (Frizzled-7) was predicted to be a prime target of miR-1. Since our findings 
suggested that miR-1 had an important role in regulating OA-related gene expression in 
chondrocytic cells, we proceeded to investigate whether the effects of miR-1 were mediated by 
its binding to FZD7. This would inhibit Wnt binding to FZD7 and prevent β-catenin activation 
[45], thereby reducing the downstream expression of catabolic genes. Although blocking FZD7 
to reduce Wnt/β-catenin signalling has been performed in other studies, which resulted in 
growth inhibition in a range of tumour types [46, 47], modulation of this same pathway has 
never been attempted in OA research. For the first time, our study demonstrated an important 
functional link between miR-1-FZD7 binding and Wnt/β-catenin signalling in chondrocytes. 
The regulation of catabolic gene expression through this pathway might contribute to changes 
in chondrocyte phenotype and play a role in the development of OA. We confirmed that miR-
1 has a specific binding site in FZD7, and miR-1 binding reduces the mRNA and protein 
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expression of FZD7 in chondrocytic cells. This results in increased levels of phosphorylated β-
catenin that suppresses downstream β-catenin signalling. Other studies have shown that 
reduced activation of the Wnt/β-catenin pathway is associated with the downregulation of 
catabolic enzymes implicated in cartilage degradation and OA progression [39, 40].  
 
There were some limitations in our study. First, although the findings from the luciferase 
reporter assay and gene expression analysis suggested potential interactions between miR-1 
and the 3’UTR of FZD7, the results were relative and did not indicate direct binding. The 
precise mechanism for miR-1 regulation of Wnt/β-catenin signalling through FZD7 needs to 
be confirmed in future studies. Second, chondrocyte hypertrophy plays a key role in the 
development and progression of OA, which is partly associated with the activation of Wnt/β-
catenin signalling [48, 49]. Although all of the gene markers we have examined in this study 
are relevant to chondrocyte hypertrophy, namely MMP-9, MMP-13, BMP-2, ADAMTS5 and 
COL2A1, there are other markers that are closely associated with hypertrophic differentiation, 
such as COL10A1 and RUNX2, as well as a range of markers associated with other pathways 
including inflammatory signalling and mineralisation [48]. Given the known association 
between miR-1 and late-stage chondrocyte differentiation [27], it would be highly relevant to 
investigate the possible pathways by which miR-1 may regulate chondrocyte hypertrophy 
through Wnt/β-catenin signalling in future studies. Third, our study was performed using a 
chondrocytic cell model that does not fully replicate the characteristics of native tissues. This 
model does not allow the demonstration of a causal connection between miR-1 induced 
alterations in Wnt/β-catenin signalling and changes in cartilage degradation at the tissue level. 
The in vitro effects of miR-1 overexpression observed in this study will need to be verified in 





To our knowledge, this study provides the first evidence of a functionally important role for 
miR-1 regulation of the Wnt/β-catenin pathway in chondrocytes. By inhibiting Wnt/β-catenin 
signalling through FZD7, miR-1 overexpression in chondrocytes can lead to changes in gene 
expression that potentially contribute to attenuating OA pathogenesis. It should be noted that a 
range of miRNAs implicated in cancer have been shown to regulate Wnt/β-catenin signalling 
through FZD7 and other Frizzled receptors [50], some of which may be associated with 
pathways relevant to OA development and warrant further investigation. Future studies will be 
necessary to explore the functional and clinical implications of miR-1 and other relevant 
miRNAs in OA treatment. Although several clinical trials are currently ongoing for miRNA-
based treatment of several diseases including hepatitis C, liver cancer and heart failure [51, 52], 
miRNA-based treatment of OA will present unique challenges due to the relative 
inaccessibility of chondrocytes within the joint structure. Nevertheless, our work provides new 
evidence for the role of miR-1 in the regulation of chondrocyte phenotype and gene expression, 
which may be useful for future studies exploring epigenetic mechanisms of OA pathogenesis 
and developing related treatments. 
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